<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995406</url>
  </required_header>
  <id_info>
    <org_study_id>ISIT-TB 001</org_study_id>
    <nct_id>NCT04995406</nct_id>
  </id_info>
  <brief_title>Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis</brief_title>
  <acronym>ISIT-TB</acronym>
  <official_title>Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis With the ISIT-TB Prototype in Adults Living in a High Burden Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMérieux</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMérieux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ISIT-TB Prototype is a diagnostic assay based on a transcriptional blood signature suggestive&#xD;
      of the detection of Mycobacterium tuberculosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This device will be investigated for use as a screening tool to facilitate diagnosis of ATB&#xD;
      in conjunction with risk assessment, clinical context and diagnostic information. Whole blood&#xD;
      samples will be collected in Tempus™ Blood RNA Tubes and processed on an automatized&#xD;
      platform. The detection of a combination of under or over-expressed selected genes,&#xD;
      constituting a transcriptional signature, will allow the characterization of ATB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of performance of the diagnostic tool</measure>
    <time_frame>Time to bacteriological confirmation 60 days</time_frame>
    <description>Determination of the specificity and sensitivity of the diagnostic assay ISIT-TB Prototype for TB in a population living in a high-burden country</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">710</enrollment>
  <condition>TUBERCULOSIS, PULMONARY</condition>
  <arm_group>
    <arm_group_label>Active TB ATB</arm_group_label>
    <description>Participants with active tuberculosis with diagnosis confirmed by GeneXpert and/or culture positivity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latent Tuberculosis Infections LTBI</arm_group_label>
    <description>Participants with presumed latent TB infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls HC</arm_group_label>
    <description>Participants who do not have Active or Latent tuberculosis or other pathologies investigated in this study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-tuberculous symptomatic participants</arm_group_label>
    <description>This cohort refers to participants who are known with chronic respiratory conditions and present with one or more signs and symptoms suggestive of TB, but in whom microbiological testing is negative.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ISIT-TB prototype</intervention_name>
    <description>Diagnostic assay able to identify active tuberculosis using a patient blood sample processed on an automatized system within an hour</description>
    <arm_group_label>Active TB ATB</arm_group_label>
    <arm_group_label>Healthy controls HC</arm_group_label>
    <arm_group_label>Latent Tuberculosis Infections LTBI</arm_group_label>
    <arm_group_label>Non-tuberculous symptomatic participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Active TB cases will be prospectively recruited from the primary care TB clinics and&#xD;
        participating hospitals. Healthy adults will be recruited using the healthy participant&#xD;
        database of the participating hospitals. For LTBI population, individuals presenting to&#xD;
        primary care facilities for reasons other than suspected TB will be approached and invited&#xD;
        to participate as possible LTBI should they be assessed as being at increased risk for TB&#xD;
        infection as described in the inclusion/exclusion criteria. Non-infectious respiratory&#xD;
        disease controls will be recruited from the participing hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptoms suggestive of TB disease: cough for more than two weeks plus at least one of&#xD;
             the following: fever, malaise, weight loss, night sweats, haemoptysis, chest pain or&#xD;
             loss of appetite.&#xD;
&#xD;
          -  Willingness to give consent to take part in the study.&#xD;
&#xD;
          -  Aged &gt;18 years old.&#xD;
&#xD;
          -  Healthy control : no history of TB treatment, no respiratory symptoms, no evidence of&#xD;
             active infectious disease, no history of close contacts of active pulmonary TB&#xD;
             patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman&#xD;
&#xD;
          -  A person who has received treatment for active TB or LTBI in the past 24 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keertan Dheda, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurore FLEURIE, PhD</last_name>
    <phone>(0) 4 78 87 20 00</phone>
    <phone_ext>+33</phone_ext>
    <email>aurore.fleurie@biomerieux.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Mycobacterium infections</keyword>
  <keyword>Bacterial infections</keyword>
  <keyword>Diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

